Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Difelikefalin acetate in Chronic Kidney Diseases: NCT07526324 Clinical Landscape Report 2026
16 October 2026
NCT07526324 clinical landscape for Chronic Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in metastatic non-small cell lung cancer: NCT07535463 Clinical Landscape Report 2026
16 October 2026
NCT07535463 clinical landscape for metastatic non-small cell lung cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Tislelizumab in Advanced Lung Non-Small Cell Carcinoma: NCT07528274 Clinical Landscape Report 2026
16 October 2026
NCT07528274 clinical landscape for Advanced Lung Non-Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Pemetrexed Dipotassium in Resectable Lung Non-Small Cell Carcinoma: NCT07538193 Clinical Landscape Report 2026
16 October 2026
NCT07538193 clinical landscape for Resectable Lung Non-Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Datopotamab Deruxtecan in EGFR-mutated non-small Cell Lung Cancer: NCT07535437 Clinical Landscape Report 2026
16 October 2026
NCT07535437 clinical landscape for EGFR-mutated non-small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
ANS-02 in EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma: NCT07538804 Clinical Landscape Report 2026
16 October 2026
NCT07538804 clinical landscape for EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context…
9 min read
Sacituzumab tirumotecan in EGFR-mutated non-small Cell Lung Cancer: NCT07545213 Clinical Landscape Report 2026
16 October 2026
NCT07545213 clinical landscape for EGFR-mutated non-small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
KQB-368 in Advanced Malignant Solid Neoplasm: NCT07542704 Clinical Landscape Report 2026
16 October 2026
NCT07542704 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
YMN-136 Vaccine in Advanced Lung Non-Small Cell Carcinoma: NCT07561723 Clinical Landscape Report 2026
16 October 2026
NCT07561723 clinical landscape for Advanced Lung Non-Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Ademetionine 1,4-Butanedisulfonate in Adenoma: NCT07582003 Clinical Landscape Report 2026
16 October 2026
NCT07582003 clinical landscape for Adenoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SR-02 in Diabetes Mellitus, Type 1: NCT07581197 Clinical Landscape Report 2026
16 October 2026
NCT07581197 clinical landscape for Diabetes Mellitus, Type 1: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Navlimetostat in Advanced Lung Non-Small Cell Carcinoma: NCT07579221 Clinical Landscape Report 2026
16 October 2026
NCT07579221 clinical landscape for Advanced Lung Non-Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development whit…